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Background:  Red  cell  exchange/transfusion  is  frequently  used  in  the  management
of  patients  with  medical  complications  related  to  acute  severe  sickle  cell  disease
(SCD).  However,  peripheral  venous  access  is  often  difﬁcult  without  central  venous
catheters  (CVCs)  in  adult  patients  with  moderate  or  severe  SCD.
Aims:  To  review  our  experience  with  the  use  of  the  PORT-A-CATH® device  in  sixteen
patients  with  SCD  undergoing  exchange  or  simple  transfusions.
Methods:  Among  a  cohort  of  550  patients  who  frequently  visited  the  inpatient  ser-
vice,  sixteen  SCD  patients  required  the  insertion  of  a  PORT-A-CATH® device.  These
patients  included  3  males  and  13  females,  aged  25—44  years  [31.1  ±  2.3;  mean  ±  SD].
A  total  of  24  PORT-A-CATH® devices  were  implanted  in  these  16  patients  during  the
study  period.  Eleven  patients  had  1  device  implanted,  three  patients  had  2  devices,
one  patient  had  3  devices,  and  one  patient  had  4  devices  implanted.
Results:  Out  of  the  24  devices  implanted,  17  required  removal,  due  to  either
infection  associated  with  sepsis  and/or  thrombosis.  The  organisms  involved  were
Candida  spp.  (3),  C.  Parapsilosis  (2),  C.  albicans  (1),  C.  famata  (1),  C.  lusitanice
(1),  Staphylococcus  spp.  (6),  and  S.  aureus  (3),  as  well  as  the  coagulase-negative
Staphylococcus  (2),  alpha  hemolytic  Streptococcus  (1),  Diphtheroid  bacilli  (2),  Pseu-
domonas  aeruginosa  (2),  Ps.  Spp.  (3),  Escherichia  coli  (3),  Klebsiella  oxytoca  (1),
Klebsiella  pneumoniae  (1),  Klebsiella  spp.  (1),  Serratia  liquefaciens  (1),  Serra-
tia  fanticola  (1),  Achromobacter  spp.  (2)  Chromobacterium  violaceum  (1),  Delftia
acidovirans  (1),  Stenotrophomonas  maltophile  (1),  Alcaligenes  faecalis  (1),  and
Enterobacter  cloacae  (1).  Two  episodes  of  documented  thrombosis  were  observed.
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One  case  presented  with  right  atrial  thrombosis/SVC  syndrome  and  the  other  case
presented  with  left  upper  arm  thrombosis.  Two  patients  died  with  ports  in  situ,  while
ﬁve  patients  had  ports  in  place  at  the  time  of  this  study.  The  median  working  life  of
the  ports  was  688.5  days  (range:  39—3925).  The  rate  of  infective  complications  was
2.63  infections  per  1000  catheter  days,  and  the  number  of  infections  was  signiﬁcantly
correlated  with  the  number  of  ports  [Pearson’s  r  =  0.66;  p  <  0.01].
Discussion:  Our  results  suggest  that  patients  with  SCD  suffer  infective  complications
associated  with  the  PORT-A-CATH®,  which  often  necessitate  its  removal.  Although
ely  useful,  their  optimal  beneﬁcial  potential  is  only  realized
roper  care  at  special  centers  well-versed  in  the  maintenance
ienced  staff.































rate of  4.33  admissions  per  life  of  the  port  (range:
1—14 admissions).
®these  devices  are  extrem
if  the  patients  receive  p
of  such  devices  by  exper
©  2011  King  Saud  Bin  Ab
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Introduction
Sickle  cell  disease  (SCD)  is  quite  prevalent  in  the
Sultanate  of  Oman  with  a  carrier  rate  of  approx-
imately 6%  and  a  sickle  cell  disease  rate  of  0.2%
[1—3]. SCD  is  a  complex  multi-system  disease  char-
acterized  by  the  triad  of  recurrent  painful  crisis,
hemolytic  anemia,  and  a  predisposition  to  repeated
infections.  The  clinical  behavior  of  SCD  patients
is also  highly  variable,  with  many  patients  requir-
ing multiple  admissions  to  hospitals  or  emergency
rooms for  medical  attention,  especially  for  the
management  of  vaso-occlusive  crisis  (VOC).
Red cell  exchange/transfusion  constitutes  an
essential  tool  in  the  management  of  certain
patients with  SCD,  especially  those  with  moderate
to severe  VOC  episodes.  However,  due  to  repeated
hospital visits,  poor  IV  access  prevents  the  delivery
of appropriate  medical  care.  Thus,  these  patients
often require  the  placement  of  some  form  of  vas-
cular access  catheter  for  delivery  of  intravenous
medications,  blood  products,  erythrocytopheresis,
narcotics,  or  chelation  therapy.  For  these  reasons,
implantable  venous  access  devices  are  an  impor-
tant aspect  of  sickle  cell  medical  care,  particularly
devices that  can  offer  patients  reliable  long-term
venous access  [4].
Although  these  devices  are  extremely  necessary,
they pose  a  serious  risk  of  increased  morbidity
and mortality  [5].  This  increased  risk  is  due  to
higher incidence  of  infection,  thrombosis,  mechani-
cal occlusions,  and  other  complications  [6—10].  SCD
patients are  inherently  immunocompromised  and
are at  risk  of  infections  caused  by  splenic  dysfunc-
tion, medication,  or  repeated  hospital  admissions
with exposure  to  potent  antibiotics  and  nosocomial
pathogens.
A number  of  access  devices  are  currently  used
in treatment  of  these  patients,  including  tun-
neled  catheters  and  implantable  venous  ports  [4].
t
r
shese  devices  vary  in  their  rate  of  infection  and
ther complications,  which  are  factors  which  also
epend on  whether  the  devices  are  impregnated
ith antibiotics.  There  is  conﬂicting  evidence  in
he available  literature  regarding  the  use  of  these
evices  and  their  rates  of  complications.
We retrospectively  evaluated  outcomes  of  the
se of  a  common  venous  implantable  device,
amely, ‘‘PORT-A-CATH®,’’  in  SCD  patients  from
996 to  the  date  of  this  publication.  Our  aim  was  to
ssess the  infectious  complications  associated  with
hese devices,  document  the  organisms  present,
etermine  the  length  of  these  complications,  and
nalyze the  reasons  and  risk  factors  for  removal  of
he devices.
ethods
fter  appropriate  ethical  approval  was  obtained,
 retrospective  study  of  the  medical  records  was
onducted.  To  identify  patients  with  SCD,  the  med-
cal record  database  was  searched  for  all  admissions
ith  ICD-10  codes  related  to  sickle  cell  anemia.  All
uch records  were  individually  reviewed  to  identify
atients  with  PORT-A-CATH® insertions.  This  group
ncluded  16  patients  (13  SS  homozygote;  3  S+ Thal
ouble  heterozygote)  seen  between  1996  and  2011.
 total  of  24  ports  were  placed  in  this  group  of
atients.  The  group  consisted  of  13  females  and  3
ales, with  ages  ranging  from  25  to  44  years  (mean:
1.1 years)  (Table  1).  These  patients  had  moderate
o severe  SCD,  as  deﬁned  by  the  Sickle  Cell  Cooper-
tive  Group  criteria  [11]  with  an  average  admissionAll  patients  who  required  PORT-A-CATH inser-
ion presented  with  poor  venous  access  and
equired the  device  for  exchange  blood  transfu-
ions during  episodes  of acute  VOC,  intravenous
Complications  of  PORT-A-CATH® in  SCD  
Table  1  Patient  characteristics.
Age  (years)
Mean  ±  SD  31  ±  6
Range  25—44
Males  (%)  3  (18.75)
Females  (%)  13  (81.25)
Genotype
SS  homozygotes  (%) 13(81.25)
S+ Thal  double
heterozygotes  (%)
3(18.75)
Median  age  at  port  insertion
(years)
31
Duration  of  port  (days)  688  [range:
39—3925]
No.  of  infections
All  cases,  n  (%)  28  (100)
Gram-positive,  n  (%)  12  (42.9)
Gram-negative,  n  (%)  12  (42.9)
Fungal,  n  (%)  4  (14.2)




Penicillin  V,  n  (%) 14  (87.5)







































































dministration  of  medications,  and  in  some
atients, long-term  exchange  transfusion  therapy.
All PORT-A-CATH® devices  inserted  were  the
ight-weight and  durable  titanium/polyurethane
ortal  reservoir  type  that  were  kink-resistant,  bio-
ompatible,  MRI-compatible,  latex-free,  PVC-free,
nd radiopaque  [Celsite®, Aesculap,  Inc.,  Center
alley,  PA,  USA].  Infections  were  deﬁned  using
he Center  for  Disease  Control  (CDC)  criteria  for
atheter-related  blood  stream  infections  [12].
tatistical analysis
ata  are  expressed  as  means  and  standard  devi-
tions  (±SD).  Port  complications  were  correlated
sing Pearson’s  correlation  coefﬁcient.  Differences
ere  considered  signiﬁcant  at  p  <  0.05  levels,  and
ll analyses  were  performed  using  SPSS  version  14.0
or Windows.
esults
 total  of  24  PORT-A-CATH® devices  were  implanted
n 16  patients  during  the  study  period.  Eleven
atients had  a  single  device  implanted,  three
atients had  2  devices,  one  patient  had  3  devices,
nd one  had  4  devices  implanted.  Table  2  shows





urvival  times.  There  were  a  total  of  16,523  days  of
atheter use,  ranging  from  39  to  3925  days  (mean:
88.5 days).
Seventeen  ports  (70.83%)  required  removal
ither due  to  infection  associated  with  sepsis
nd/or thrombosis.  The  presence  of  catheter-
ssociated infection  was  indicated  by  bacterial  or
ungal growth  in  blood  cultures  obtained  through
he port  with  detection  of  growth  within  72  h of
lating.  On  average,  at  least  1.7  organisms  were
solated  from  each  patient  per  port  prior  to  its
emoval  with  a range  of  1—6  different  organisms.
able 3  shows  the  number  and  distribution  of  the
athogens  isolated  during  the  infective  episodes.
ungal  microorganisms  were  isolated  in  19.5%  of
ases, Gram-positive  organisms  in  34.14%,  and
ram-negative  organisms  in  the  remaining  46.34%
f the  cases.
Two patients  died  with  the  port  in  situ.  One
atient died  while  in  the  hospital  with  SCD-related
omplications,  and  the  other  patient  experienced
udden death  at  home.  The  rate  of  infective  compli-
ations  was  2.63  infections  per  1000  catheter  days
n this  group  of  patients.
iscussion
ORT-A-CATH® is  an  extremely  useful  device  for
atients  who  require  ongoing  therapy  but  present
oor venous  access.  However,  these  devices  are
ssociated  with  a series  of  complications  that
nclude occlusion,  infection,  and  thrombosis.  We
dentiﬁed no  signiﬁcant  correlation  between  the
umber of  infections  and  penicillin  V prophy-
axis [r  =  0.127],  hydroxyurea  therapy  [r  =  −0.31],
r splenectomy  [r  =  −0.155].  However,  we  detected
 strong  correlation  between  the  number  of  infec-
ions  and  the  number  of  ports  [Pearson’s  r  =  0.663,
 <  0.01].
One  of  the  most  common  causes  for  the  removal
f the  device  in  this  cohort  of  patients  was  infec-
ion, similar  to  data  presented  in  other  studies
4,13,14]. Infections  were  documented  in  all  ports
100%] at  a rate  of  2.63  infections  per  1000  catheter
ays. However,  this  rate  is  quite  low  compared
o the  rates  reported  in  other  studies  of  simi-
ar patient  populations  [10,13—15]. Jeng  et  al.
10], in  a  study  of  19  SCD  patients,  reported  a
igh frequency  of  infectious  complications  with  5.5
nfections  per  1000  catheter  days.  McCready  et  al.
13] reported  on  5  patients  with  SCD  with  5 chest
orts,  documenting  a  100%  infection  rate,  as  was
he case  in  our  cohort.  Phillips  et  al.  [14],  in  a
tudy of  eight  SCD  patients  with  10  chest  ports,
60  S.  Alkindi  et  al.
Table  2  Correlation  of  treatment  with  port  infections  and  port  survival  times.
Unique  patient  number
#1  #2  #3  #4  #5  #6  #7  #8  #9  #10  #11  #12  #13  #14  #15  #16
Penicillin  V −  +  +  +  +  +  +  +  +  +  +  +  +  +  +  −
Hydroxyurea − − + + + + −  +  −  −  −  +  −  +  −  −
Splenectomy − − + − + − + −  −  +  −  +  −  −  +  +
No.  of  ports  2  4  1  2  1  1  1  3  1  2  1  1  1  1  1  1
No.  of  organisms  3  6  3  1  4  1  1  4  4  6  1  1  2  3  1  1
No.  of  days  port
no.  1
708  653  47  562  621  3925  39  714  105  41  1987  1124  760  317  426  418
No.  of  days  port
no.  2
302  198  —  487  —  —  —  528  —  660  —  —  —  —  —  —
No.  of  days  port
no.  3
—  594  —  —  —  —  —  502  —  —  —  —  —  —  —  —
No.  of  days  port
no.  4
—  805  —  —  —  —  —  —  —  —  —  —  —  —  —  —
Total  no.  of  days  1010  2250  47  1049  621  3925  39  1744  105  701  1987  1124  760  317  426  418
No.  of  infec-
tions/1000  port
days
2.97  2.66  42  0.95  6.44  0.25  25  2.29  38  8.55  0.5  0.88  1.31  3.2  2.3  2.4
Average  no.
days/port
688.5  [range:  39—3925]
Table  3  Number  and  type  of  organisms  isolated  during  infective  episodes.
Organisms Unique  patient  numbers
#1 #2  #3  #4  #5  #6  #7  #8  #9  #10  #11  #12  #13  #14  #15  #16
No.  of  ports 2  4  1  2  1  1  1  3  1  2  1  1  1  1  1  1
No.  of  organisms  3  6  3  1  4  1  1  4  4  6  1  1  2  3  1  1
Gram-positive  [n  =  14;  34.1%]
Staphylococcus  spp.  +  +  +  +  +  +
Staphylococcus  aureus + +  +
Coag-negative  Staphyloccous + +
Alpha  hemolytic  Streptococcus +
Diphtheroid  bacilli + +
Gram-negative  [n  =  19;  46.4%]
Klebsiella  spp. +
Klebsiella  pneumoniae +
Klebsiella  oxytoca  +
Seratia  liquefaciens +
Seratia  fanticola +
Pseudomonas  spp. + + +
Pseudomonas  aeruginosa  +  +
E.  coli  +  +  +
Enterobacter  cloacae  +
Alcaligenes  fecalis  +
Achromobacter  spp.  +  +
Delﬁa  acidomiran  +
Chromobacterium  violaceum  +
Stenotrophomonas  maltophilia  +
Fungi  [n  =  8;  19.5%]
Candida  spp.  +  +  +
Candida  albicans  +
Candida  famata  +
Candida  parapilosis  +  +





































































































pomplications  of  PORT-A-CATH® in  SCD  
eported  a  50%  infectious  complication  rate  requir-
ng port  removal  compared  to  a  3%  incidence  in
alignancies.  Interestingly,  the  same  study  also
eported  a  complication  rate  3.3  times  lower  with
roviac catheters  than  with  ports  in  SCD  patients.
ll of  the  infections  in  these  cohorts  were  demon-
trated via  culture  and  received  adequate  and
ppropriate  intravenous  antibiotics  for  sufﬁcient
engths of  time  before  the  decision  was  made
o remove  the  devices;  however,  the  studies  did
ot always  include  surveillance  of  catheter-related
lood stream  infections  [15].
We observed  a  rise  in  Gram-negative  and
ater born-pathogens,  which  were  highly  resis-
ant to  antibiotics  (Table  3).  This  ﬁnding  contrasts
ith  previous  studies  that  reported  Staphylococcus
ureus as  the  most  commonly  isolated  organism  in
CD patients  with  ports  [4].  Furthermore,  we  iden-
iﬁed a  large  number  of  Candida  infections  in  this
ohort,  which  is  a  ﬁnding  that  agrees  with  pre-
ious reports  [16].  The  overall  high  incidence  of
nfections  encountered  in  SCD  patients  is  a  multi-
actorial  phenomenon.  It  is  well-established  that
atients  with  SCD  are  predisposed  to  infections
rom encapsulated  organisms,  such  as  S.  pneu-
onia,  Salmonella, and  H.  inﬂuenza, because  of
utosplenectomy  and  defective  opsonization  [17].
owever,  increased  susceptibility  to  infections  may
lso be  attributed  to  iron  overload  and  altered
hagocyte function  caused  by  repeated  transfu-
ions [18].  Other  potential  causes  for  infection
ould be  inappropriate  care  and  use  of  the  port,  as
ell as  misuse  of  the  port  for  injections  of  recre-
tional drugs,  mainly  narcotics.
Ports from  the  9  patients  in  this  cohort  grew  mul-
iple  organisms  [range:  2—6,  median:  4  organisms].
mong these  patients,  5  patients  had  a  single  port,
hich was  removed  following  the  growth  of  multi-
le organisms,  while  the  remaining  4  patients  had
ultiple ports  with  infections,  which  were  subse-
uently  removed.  Numbers  of  infections/1000  port
ays were  high  in  patients  #3,  #7,  and  #9  (Table  2).
he fact  that  these  three  patients  only  had  a  sin-
le port  with  a  relatively  short  catheter  duration
47, 39,  and  105  days,  respectively)  is  probably  a
eﬂection of  their  disease  severity  as  a  risk  fac-
or (i.e.,  numerous  VOC  incidents  with  varying
ospital stay  durations)  rather  than  poor  catheter
ygiene.  In  the  two  patients  in  whom  the  ports
ad to  be  removed  early  (e.g.,  within  100  days),
atients  #3  and  #7,  the  pattern  of  the  infectious
rganisms were  predominantly  nosocomial.  Patient
3 grew  two  signiﬁcant  Gram-negative  pathogens,
lebsiella oxytoca  and  Serratia  fanticola, whereas
atient  #7  grew  coagulase-negative  Staphyloccous





nfectious  process  was  initiated  as  a consequence  of
nsertion of  the  port  in  these  three  patients.  How-
ver, our  policy  now  requires  that  patients  receive
 betadine  bath  24  h prior  to  the  insertion  of  these
ines. Additionally,  all  patients  are  given  two  doses
f vancomycin  following  the  insertion.  To  date,  we
ave not  observed  any  immediate  catheter-related
orbidities  or  complications  with  this  new  regimen.
Among  all  infected  ports,  17  [70.83%]  were
emoved, and  the  remaining  ﬁve  [20.83%]  were
alvaged  following  adequate  therapy  with  appro-
riate  antibiotics;  these  5  salvaged  ports  remain
n use.  However,  two  additional  patients  died  with
he port  in  situ.  One  patient  died  at  the  age  of
0 years  with  acute  anemia  and  multi-organ  failure,
hile the  other  died  in  another  hospital.  Her  death
as not  related  to  the  port.  The  other  patient,
ged 35  years,  experienced  sudden  death  at  home.
lthough  he  had  a  history  of  left  upper  arm  throm-
osis,  he  refused  removal  of  the  catheter  and  was
n full  anticoagulation  at  the  time  of  his  death.
Thrombotic  complications  were  relatively  low  in
his cohort  of  patients,  a ﬁnding  that  agrees  with
revious reports  [7].  We  observed  three  patients
ho developed  thrombosis,  including  a patient  who
eveloped  right  atrial  thrombus  and  superior  vena
ava syndrome.  She  was  subsequently  found  to  have
 moderate  heterozygous  protein  C  deﬁciency.  She
eceived thrombolysis  followed  by  full  anticoagula-
ion. Incidentally,  another  patient  who  developed
hrombosis in  the  upper  limb  on  the  same  side  of
he port  received  full  anticoagulation  because  he
efused removal  of  the  port.  The  patient  has  had
he device  for  over  10  years.
Since  the  year  2000,  we  have  used  low-intensity
nticoagulation  with  1  mg  warfarin  for  all  patients
ith permanent  ﬁxtures,  unless  there  was  a  con-
raindication  to  anticoagulation  [19].  In  an  attempt
o salvage  any  blocked  lines,  it  is  our  policy  to  use
rokinase  in  situ  to  unblock  any  small  thrombus,
hich is  an  approach  that  is  usually  successful.
We observed  that  the  longest  serving  ports
ere in  two  patients  who  had  them  for  3925  and
987 days,  respectively;  both  patients  were  cared
or exclusively  in  our  center.  This  ﬁnding  agrees
ith results  in  the  literature  showing  that  devices
urvive  longer  if  they  are  handled  by  experienced
taff from  the  same  center  at  all  times  [4].
Patients with  severe  or  moderately  severe
isease often  require  repeated  venous  access
or optimal  medical  care  [5].  The  cohort  of
atients studied  in  this  report  who  required  central
enous  access  were  also  patients  with  moderate
o severe  disease  based  on  their  hospitalization
atterns (average  admissions  >  4).  These  patients










medications  and  were  thus  more  likely  to  become
colonized with  resistant  organisms,  as  was  seen  in
this study.
Five  devices  were  still  in  use  at  the  end  of
this study.  Although  these  patients  had  repeated
episodes of  infection,  their  ports  were  salvaged  by
appropriate  intravenous  antibiotics,  with  negative
cultures  being  subsequently  observed.  Therefore,
our study  emphasizes  the  need  to  recommend  a
policy guideline  whereby  patients  are  encouraged
to attend  the  same  center  at  all  times.  The  guide-
lines  should  encompass  appropriate  training  for  a
dedicated nursing  staff  that  can  exclusively  handle
these ports  in  order  to  preserve  functional  utility
and maximize  use,  while  managing  low-intensity
anticoagulation  with  warfarin  to  prevent  throm-
bosis.  In  our  service,  such  recommendations  have
become the  standard  of  care  for  patients  requiring
insertion of  vascular  access  devices.
The major  weakness  of  this  study  was  the  limited
cohort  size.  This  study  showed  that  approximately
2.9% of  the  550  SCD  patients  treated  at  this  center
required  a  PORT-A-CATH® insertion  over  a  15-year
observation  period.  However,  we  must  emphasize
that the  trends  observed  in  this  study  cannot  lead
to speciﬁc  conclusions  because  of  the  small  sam-
ple size.  A  larger  multi-center  prospective  study  is
warranted  to  substantiate  our  ﬁndings.
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